Bicycle Therapeutics (BCYC) Preferred Stock Liabilities (2018 - 2019)
Bicycle Therapeutics (BCYC) reported Preferred Stock Liabilities of $54.6 million for Q1 2019, up 30.61% on a YoY basis from $41.8 million in Q1 2018, and up 112.07% quarter-over-quarter from $25.8 million in Q4 2018.
Bicycle Therapeutics (BCYC) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Bicycle Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $54.6 million in Q1 2019.
- For the quarter ending Q1 2019, Preferred Stock Liabilities rose 30.61% year-over-year to $54.6 million; the trailing twelve-month figure through Mar 2019 stood at $54.6 million (up 30.61% YoY), and the FY2018 full-year result was $25.8 million, down 38.41% from the prior year.
- Preferred Stock Liabilities for Q1 2019 stood at $54.6 million, up from $25.8 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $54.6 million in Q2 2018, with the low at $25.8 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Bicycle Therapeutics | 278.04 Mn | 278.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 54.62 Mn |
| Dec 31, 2018 | 25.76 Mn |
| Jun 30, 2018 | 54.62 Mn |
| Mar 31, 2018 | 41.82 Mn |